Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2014-02-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/17512433.2014.884457PMID 24494793
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of infections due to resistant Staphylococcus aureus.

  2014cited by this paper
• Acute care surgery.

  2014cited by this paper
• Evaluation of the Effect of a Supratherapeutic Dose of Intravenous Ceftaroline Fosamil on the Corrected QT Interval

  2013cited by this paper
• Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

  2013cited by this paper
• Management of MRSA/GISA, VISA Endocarditis

  2013influential reference
• Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Asia.

  2013cited by this paper
• Current and prospective treatments for multidrug-resistant gram-positive infections

  2013cited by this paper
• How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function

  2013cited by this paper
• An Evaluation of Hyperkalemia and Serum Creatinine Elevation Associated With Different Dosage Levels of Outpatient Trimethoprim-Sulfamethoxazole With and Without Concomitant Medications

  2013cited by this paper
• Single- and Multiple-Dose Study To Determine the Safety, Tolerability, and Pharmacokinetics of Ceftaroline Fosamil in Combination with Avibactam in Healthy Subjects

  2013cited by this paper
• Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community‐acquired bacterial pneumonia

  2013cited by this paper
• Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).

  2013cited by this paper
• Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).

  2013cited by this paper
• CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections

  2012cited by this paper
• Ceftaroline

  2012cited by this paper
• Summary of ceftaroline fosamil clinical trial studies and clinical safety.

  2012cited by this paper
• Efficacy of Human Simulated Exposures of Ceftaroline against Phenotypically Diverse Enterobacteriaceae Isolates

  2012cited by this paper
• Ceftaroline Fosamil in the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections

  2012cited by this paper
• Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.

  2011cited by this paper
• Efficacy of Human Simulated Exposures of Ceftaroline Administered at 600 Milligrams Every 12 Hours against Phenotypically Diverse Staphylococcus aureus Isolates

  2011cited by this paper
• Efficacy of the New Lantibiotic NAI-107 in Experimental Infections Induced by Multidrug-Resistant Gram-Positive Pathogens

  2011cited by this paper
• Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections in Hospitalized Patients

  2011cited by this paper
• Multistep Resistance Development Studies of Ceftaroline in Gram-Positive and -Negative Bacteria

  2011cited by this paper
• Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

  2011cited by this paper
• Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

  2011cited by this paper
• Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis.

  2010cited by this paper
• Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

  2010cited by this paper
• Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

  2010cited by this paper
• Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe.

  2010cited by this paper
• Guidance for Industry Non-Inferiority Clinical Trials

  2010cited by this paper
• Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?

  2010cited by this paper
• CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

  2010cited by this paper
• Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae.

  2010cited by this paper
• CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

  2010cited by this paper
• Effect of Ceftaroline on Normal Human Intestinal Microflora

  2010cited by this paper
• Affinity of Ceftaroline and Other β-Lactams for Penicillin-Binding Proteins from Staphylococcus aureus and Streptococcus pneumoniae

  2010cited by this paper
• In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates

  2010cited by this paper
• The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study.

  2009cited by this paper
• In Vivo Activity of a Novel Anti-Methicillin-Resistant Staphylococcusaureus Cephalosporin, Ceftaroline, against Vancomycin-Susceptible and -Resistant Enterococcusfaecalis Strains in a Rabbit Endocarditis Model: a Comparative Study with Linezolid and Vancomycin

  2009cited by this paper
• Vancomycin Ototoxicity: a Reevaluation in an Era of Increasing Doses

  2008cited by this paper
• Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics.

  2008cited by this paper
• National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections.

  2008cited by this paper
• Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

  2008cited by this paper
• Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

  2008cited by this paper
• Skin, Soft Tissue, Bone, and Joint Infections in Hospitalized Patients: Epidemiology and Microbiological, Clinical, and Economic Outcomes

  2007influential reference
• In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

  2007cited by this paper
• In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model

  2007cited by this paper
• Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus, United States, 1999–2005

  2007cited by this paper
• Trends in US Hospital Admissions for Skin and Soft Tissue Infections

  2007cited by this paper
• Staphylococcus aureus–associated Skin and Soft Tissue Infections in Ambulatory Care

  2006cited by this paper
• Pharmacodynamics of a New Cephalosporin, PPI-0903 (TAK-599), Active against Methicillin-Resistant Staphylococcus aureus in Murine Thigh and Lung Infection Models: Identification of an In Vivo Pharmacokinetic-Pharmacodynamic Target

  2006cited by this paper
• Serotonin toxicity associated with the use of linezolid: a review of postmarketing data.

  2006cited by this paper
• Linezolid-associated toxic optic neuropathy

  2006cited by this paper
• A review of linezolid: the first oxazolidinone antibiotic

  2004cited by this paper
• Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management.

  2004cited by this paper
• Peripheral neuropathy associated with prolonged use of linezolid.

  2004cited by this paper
• TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties.

  2003cited by this paper
• Vancomycin resistant Staphylococcus aureus in the United States

  2002cited by this paper
• Cephalosporin allergy.

  2002cited by this paper
• Performance standards for antimicrobial susceptibility testing

  2001cited by this paper
• Linezolid and reversible myelosuppression.

  2001cited by this paper
• Cephalosporin allergy.

  2001cited by this paper
• Linezolid and reversible myelosuppression.

  2001cited by this paper
• The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.

  1998cited by this paper

• Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?

  2024cites this paper
• New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics

  2020cites this paper
• Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient

  2019cites this paper
• Comprehensive Guidance for Antibiotic Dosing in Obese Adults

  2017cites this paper
• Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System

  2017cites this paper
• Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options)

  2017cites this paper
• Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?

  2017cites this paper
• Diabetic foot infection: Antibiotic therapy and good practice recommendations

  2017cites this paper
• Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance

  2016cites this paper
• Obésité et antibiothérapie

  2016cites this paper
• Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia

  2015cites this paper
• Bacterial Infections and Drug Resistant Pathogens ( H Wisplinghoff , Section Editor ) Diagnostic and Treatment Considerations for Prosthetic Joint Infections : Sonication and New Gram-Positive Agents

  2015cites this paper